This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Caprogel

Valeant Pharmaceuticals International, Inc.

Drug Names(s): aminocaproic acid

Description: Caprogel is a topical formulation containing aminocaproic acid which inhibits the activation of plasminogen. Plasminogen dissolves blood clots; its inhibition promotes blot clotting and prevents further bleeding.

Deal Structure: This product was originally developed by ISTA. In June 2012, Bausch and Lomb completed its acquisition of ISTA.

Bausch + Lomb and Valeant
In May 2013, Valeant and Bausch + Lomb announced that they have entered into a definitive agreement under which Valeant will acquire Bausch + Lomb for $8.7 billion in cash.

In August 2013, Valeant announced it has completed the acquisition of Bausch + Lomb.


Caprogel News

Pink Sheet Trademark Review


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug